Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STAT3 | P40763 | 1/20 | 0.42 |
| ▸ | STAT1 | P42224 | 1/20 | 0.42 |
| ▸ | HTR1A | P08908 | 2/20 | 0.38 |
| ▸ | HTR1D | P28221 | 1/20 | 0.38 |
| ▸ | HTR1B | P28222 | 1/20 | 0.38 |
| ▸ | THRA | P10827 | 7/20 | 0.37 |
| ▸ | THRB | P10828 | 6/20 | 0.37 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 3/20 | 0.36 |
| ▸ | MLNR | O43193 | 1/20 | 0.35 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.35 |
| ▸ | ESR1 | P03372 | 1/20 | 0.35 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.35 |
| ▸ | PGR | P06401 | 1/20 | 0.35 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.35 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL586080 | 0.99 | STAT3 (0.41) | STAT3STAT1HTR1AHTR1DHTR1B | |
| SCHEMBL586541 | 0.98 | STAT3 (0.42) | STAT3STAT1HTR1AHTR1DHTR1B | |
| Hydrochloric Acid SCHEMBL585790 | 0.97 | STAT3 (0.41) | STAT3STAT1HTR1AHTR1DHTR1B | |
| SCHEMBL12057394 | 0.97 | STAT3 (0.41) | STAT3STAT1HTR1AHTR1DHTR1B | |
| SCHEMBL584949 | 0.95 | STAT3 (0.47) | STAT3STAT1CHEK2ACHEALDH1A1 | |
| SCHEMBL15673545 | 0.94 | STAT3 (0.46) | STAT3STAT1HTR1AMLNRNR1I2 | |
| SCHEMBL17722680 | 0.94 | STAT3 (0.46) | STAT3STAT1HTR1AMLNRNR1I2 | |
| Bromide SCHEMBL5015919 | 0.94 | STAT3 (0.46) | STAT3STAT1CHEK2ACHEALDH1A1 | |
| Hydrochloric Acid SCHEMBL585263 | 0.94 | STAT3 (0.46) | STAT3STAT1CHEK2ACHEMAOA | |
| SCHEMBL12057418 | 0.93 | STAT3 (0.40) | STAT3STAT1HTR1AHTR1DHTR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9326511-B2 | Methods of inhibiting microbial biofilms | DESTINY PHARMA LIMITED (GB) | 2016-05-03 | — | — | US | claimed |
| EP-2355816-B1 | PORPHYRIN COMPOUNDS FOR KILLING, INHIBITING OR PREVENTING THE GROWTH OF MICROBIAL BIOFILMS | DESTINY PHARMA LTD (GB) | 2014-05-14 | — | — | EP | claimed |
| EP-1768666-B1 | NOVEL USES OF PORPHYRIN COMPOUNDS | DESTINY PHARMA LTD (GB) | 2012-02-15 | — | — | EP | claimed |
| US-20110262511-A1 | Novel Uses | DESTINY PHARMA LIMITED (GB) | 2011-10-27 | — | — | US | claimed |
| EP-1578750-B1 | CATIONIC PORPHYRIN DERIVATIVES AS ANTIBACTERIAL AGENTS | DESTINY PHARMA LTD (GB) | 2007-11-21 | — | — | EP | claimed |
| US-9326511-B2 | Methods of inhibiting microbial biofilms | DESTINY PHARMA LIMITED (GB) | 2016-05-03 | — | — | US | disclosed |
| EP-2355816-B1 | PORPHYRIN COMPOUNDS FOR KILLING, INHIBITING OR PREVENTING THE GROWTH OF MICROBIAL BIOFILMS | DESTINY PHARMA LTD (GB) | 2014-05-14 | — | — | EP | disclosed |
| US-20110262511-A1 | Novel Uses | DESTINY PHARMA LIMITED (GB) | 2011-10-27 | — | — | US | disclosed |
| EP-2355816-A2 | NOVEL USES | Destiny Pharma Limited (GB) | 2011-08-17 | — | — | EP | disclosed |
| US-7977474-B2 | Uses of porphyrin compounds | DESTINY PHARMA LTD. (GB) | 2011-07-12 | — | — | US | disclosed |
| WO-2010046663-A2 | NOVEL USES | DESTINY PHARMA LIMITED (GB) | 2010-04-29 | — | — | WO | disclosed |
| US-20070167619-A1 | Novel uses of porphyrin compounds | DESTINY PHARMA LTD. (GB) | 2007-07-19 | — | — | US | disclosed |
| US-7244841-B2 | Porphyrin derivatives and their use in photodynamic therapy | DESTINY PHARMA LIMITED (GB) | 2007-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110262511-A1 | Novel Uses | XDH, F12, ZFX | STAT3 2084/4885STAT1 1133/4885HTR1A 3917/4885 |
| US-20070167619-A1 | Novel uses of porphyrin compounds | PPOX, ZFX, ZYX | STAT3 529/4885STAT1 176/4885HTR1A 3348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.